BACKGROUND AND PURPOSE: Interferon beta and @entity1638 are safe immunomodulatory treatments (IT) for @entity15 ( @entity15 ), but not always effective. New drugs are available, although they show more side-effects and unknown long-term safety profile. Anti-lipid @entity23694 ( @entity23694 ) distinguish @entity15 @entity1 with early aggressive course. We prospectively studied if IT are effective in these @entity1 or if they are candidates for more aggressive drugs as first therapeutic option. METHODS: Seventy-five @entity922 @entity1 were studied. @entity23694 and conversion to @entity15 were assessed. @entity1 suffering at least two demyelinating events within 3 years were considered eligible to start IT. RESULTS: Eighteen @entity1 showed @entity23694 (M+) and 57 lacked them (M-). All M+ @entity1 and only 25 M- @entity1 were treated. The other 32 M- @entity1 suffered less @entity15 attacks than those required to initiate treatment. IT similarly reduced relapse rate in both treated groups (P < 0.0001) and reduced Expanded Disability Status Scale (EDSS) progression in M+ @entity1 , whose EDSS score had significantly increased before treatment. EDSS did not change in M- @entity1 during follow-up, regardless if they were treated or not. CONCLUSIONS: Oligoclonal IgM bands identify @entity15 @entity1 who are candidates for early immunomodulatory treatment as IT improves their @entity146 .

XXXX patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1638 :: ('MESH:C089995', 'Chemical') :: ['Glatiramer acetate'] @entity146 :: ('MESH:D001523', 'Disease') :: ['initial aggressive disease course'] @entity23694 :: ('MESH:D053307', 'Disease') :: ['OCMB', 'oligoclonal IgM bands'] @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis'] @entity922 :: ('MESH:D013568', 'Disease') :: ['clinically isolated syndrome']
@entity15 :: (MESH:D009103,Disease) :: ['Multiple sclerosis']
